N/A
N=14
Low-Cost Platelet-Rich Plasma for Hemarthropathy
Hemarthrosis · Hemophilia
Bottom Line
View on ClinicalTrials.gov: NCT06543368 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Global Satisfaction (Numeric Rating System) — 70 Scores on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Intra articular PRP Injection (Biological)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Utah
- Primary completion
- May 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Global Satisfaction (Numeric Rating System) |
70 | — |
| SECONDARY Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) |
31; 7; 4; 21 | — |
| SECONDARY Quick Disabilities of Arm Shoulder and Hand (QuickDASH) |
22.73 | — |
| SECONDARY Foot and Ankle Outcome Score (FAOS): Function |
94.12 | — |
Summary
Orthopedic complications can be injuries or diseases that affect the bones, muscles, and joints. Hemarthropathy is due to bleeding disorders, most commonly hemophilia, and can result in severe issues related to chronic amounts of blood in the body's joints. This causes swelling, pain, and loss of joint function. A serious barrier to treating many patients with bleeding disorders creates higher health risks and costs. Platelet-rich plasma (PRP) injection is a method that can reduce the cost of care while still offering a similar standard of care for patients.
This study intends to show that low-cost PRP can be done safely in patients with bleeding disorders, without the need for expensive equipment, while monitoring patient treatment results. Study participants will receive injections for joint conditions. Being in the study requires attending 1 to 2 in-person visits at the study clinic. Participants will also complete surveys using email, text messages, in person, and/or on the phone. Participation lasts about 6 months.
Eligibility Criteria
Inclusion Criteria
- Patients of any adult age with symptomatic hemarthropathy of the ankle, knee, or elbow, based on radiographs within the last 24 months.
- Patients must have failed at least six weeks of conventional conservative treatments (such as medication or physical therapy).
Exclusion Criteria
- Exclusion criteria will include recent (last two years) surgery to the affected joint, prior joint replacement.
- Prior orthobiologic injection into the affected joint.
- Thrombocytopenia
- Inability to receive factor prior to PRP injection.
- Active systemic or local infection at the site of injection,
- Non-ambulatory patients
- Body mass index (BMI) over 50
- Recent (six month) or current corticosteroid injection/intake.
Patients with hemarthropathy in multiple joints will be eligible for up to 2 joints if multiple fit the criteria.
Data sourced from ClinicalTrials.gov (NCT06543368). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.